OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr van den Brink on a High-Fiber Dietary Intervention in Smoldering Multiple Myeloma

January 14th 2025

Marcel van den Brink, MD, PhD, discusses a high-fiber dietary intervention for early-stage plasma cell disorders designed for multiple myeloma

Dr Levy on Challenges With TROP2-Directed ADCs in NSCLC

January 14th 2025

Benjamin P. Levy, MD, shares insight on current challenges with TROP2-directed antibody-drug conjugates in NSCLC.

Dr Ruella on Access Disparities to CAR T-Cell Therapy in Minority Patients With Myeloma

January 14th 2025

Marco Ruella, MD, discusses disparities in access to commercial anti-BCMA CAR T-cell therapy among minority populations (MHPs) with multiple myeloma.

Dr Park on Patient and Disease Factors that Affect Treatment Decisions for mHSPC

January 13th 2025

Chandler Park, MD, FACP, discusses patient characteristics, disease factors, and drug mechanisms of action that influence treatment decisions in mHSPC.

Dr Ghia on a Pooled Analysis of OS Outcomes With Ibrutinib Plus Venetoclax in CLL

January 13th 2025

Paolo Ghia, MD, PhD, discusses OS outcomes with first-line ibrutinib plus venetoclax in patients with CLL vs an age-matched general European population.

Dr Piotrowska on the Importance of Genomic Profiling to Identify HER2 Mutations in NSCLC

January 13th 2025

Zosia Piotrowska, MD, MHS, discusses the importance of differentiating between HER2 alterations among patients with non–small cell lung cancer.

Dr Strickler on the Rationale for Evaluating Telisotuzumab Adizutecan in Gastric/GEJ Cancer

January 13th 2025

John H. Strickler, MD, details the rationale for evaluating telisotuzumab adizutecan in advanced gastric/GEJ cancer.

Dr Girard on Mechanisms of Action for TKIs vs ADCs in HER2-Mutated NSCLC

January 13th 2025

Nicolas Girard, MD, discusses differences in the mechanisms of action for HER2-directed TKIs vs antibody-drug conjugates in HER2-mutant NSCLC.

Dr Barata on Considerations for Molecular Testing in mCRPC

January 13th 2025

Pedro Barata, MD, discusses electing appropriate testing methods in patients with mCRPC.

Dr Tan on the Efficacy and Safety of IO-IO and IO-TKI Combination Regimens in RCC

January 11th 2025

Alan Tan, MD, discusses the IO-based combination therapies that are available for the treatment of patients with RCC.

Dr Piotrowska on Treatment Sequencing Decisions in HER2-Mutated NSCLC

January 10th 2025

Zosia Piotrowska, MD, MHS, discusses disease factors that guide treatment decision-making and sequencing for patients with HER2-mutated NSCLC.

Dr Chmielowski on the Rationale for Investigating Oncolytic Viruses in Melanoma

January 10th 2025

Bartosz Chmielowski, MD, PhD, discusses the rationale for investigating oncolytic viruses in melanoma.

Dr Hoda on Characterizing HR–Positive, HER2-Low, -Ultralow, and -Null Metastatic Breast Cancer

January 10th 2025

Raza Hoda, MD, FASCP, discusses characterizing hormone receptor–positive, HER2-low, -ultralow, and -null breast carcinoma in the metastatic setting.

Dr Ghobadi on the Efficacy and Safety of WU-CART-007 in R/R T-ALL and LBL

January 10th 2025

Armin Ghobadi, MD, discusses the efficacy and safety of WU-CART-007 in heavily pretreated patients with relapsed/refractory T-ALL and LBL.

Dr Fenske on the Omission of ASCT in Mantle Cell Lymphoma After First CR and uMRD

January 10th 2025

Timothy S. Fenske, MD, MS, discusses implications for data on the omission of auto-HCT in MCL after first CR and with undetectable MRD.

Dr Lotan on the Benefits and Complications Associated With Radical Cystectomy in BCG-Unresponsive NMIBC

January 10th 2025

Yair Lotan, MD, discusses the benefits and complications associated with radical cystectomy for patients with BCG-unresponsive NMIBC.

Dr Dronca on the FDA Approval of Subcutaneous Nivolumab in Solid Tumors

January 9th 2025

Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.

Dr Eckfeldt on the Treatment Paradigm and Current Challenges in MDS

January 9th 2025

Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.

Dr Goldsberry on PARP Inhibitor Selection in Advanced Ovarian Cancer

January 9th 2025

Whitney Goldsberry, MD, discusses considerations for selecting a PARP inhibitor in the maintenance treatment of ovarian cancer.

Dr Riess on the Investigation of Ivonescimab in Advanced NSCLC

January 9th 2025

Jonathan Wesley Riess, MD, MS, discusses data from the phase 3 HARMONi-2 trial evaluating ivonescimab vs pembrolizumab in advanced NSCLC.